Completed ICRC Studies

HPTN 039

Phase III, multi-site, randomized, double-blind, placebo-controlled study to determine whether people infected with herpes simplex virus type 2 (HSV-2), the virus that causes genital herpes, can reduce their risk of becoming infected with HIV by using acyclovir, an approved medicine that suppresses genital herpes.

 

HSV-2 suppression and HIV levels

This study is to determine whether higher doses of acyclovir lead to greater reductions in HIV levels in plasma and genital tract than the doses used in the prior studies.

 

Partners in Prevention HSV/HIV Transmission Study

Phase III, multi-site, randomized, double-blind, placebo-controlled study to determine whether the use of acyclovir by people who are infected with both HSV-2 and HIV can reduce the likelihood that they will transmit HIV to their HIV uninfected sexual partners.

 
















Member login

Search this Site | Contact Us